乌诺前列酮(Unoprostone Isopropyl) - 药物靶点：PTGFR_在研适应症：青光眼，高眼压症_专利_临床

概要

基本信息

药物类型

小分子化药

别名

13,14-dihydro-15-keto-20-ethyl PGF2α、Isopropyl unoprostone、Isopropyl unoprostone (JAN)

+ [5]

靶点

PTGFR

作用机制

PTGFR激动剂(前列腺素FP受体激动剂)

治疗领域

眼部疾病

在研适应症

青光眼高眼压症

非在研适应症

干性年龄相关性黄斑病变开角型青光眼视网膜色素变性

原研机构

R-Tech Ueno, Ltd.

在研机构

Nitto Pharmaceutical Industries Ltd.

Novartis Pharma KK

非在研机构

Sucampo Pharma Americas LLC

R-Tech Ueno, Ltd.

Sucampo Pharmaceuticals LLC

最高研发阶段批准上市

首次获批日期

美国 (2000-08-03),

开角型青光眼高眼压症

最高研发阶段(中国)-

特殊审评孤儿药 (美国)

登录后查看时间轴

结构/序列

分子式C25H44O5

InChIKeyXXUPXHKCPIKWLR-JHUOEJJVSA-N

CAS号120373-24-2

关联

15

项与乌诺前列酮相关的临床试验

JPRN-jRCT2021190021

/ Not yet recruiting临床1/2期IIT

Phase I/IIa study of unoprostone release drug (URD) for safety and efficacy assessment on retinitis pigmentosa

开始日期2020-03-02

申办/合作机构-

JPRN-UMIN000013051

/ Completed临床1/2期IIT

Topical Isopropyl Unoprostone for Rhegmatogenous Retinal Detachment: Pilot Study - Topical Isopropyl Unoprostone for Rhegmatogenous Retinal Detachment

开始日期2015-01-01

申办/合作机构-

NCT01786395

/ Terminated临床3期

Phase III Clinical Study of UF-021 for Retinitis Pigmentosa - Evaluation for a Comparative Double Masked Placebo Controlled Study Period and a Continuous Administration Period

This study is a multicenter trial performed in Japan, consisting of a comparative study period and a continuous administration period.
Effect of 0.15% UF-021 eye drops on improvement in central retinal sensitivity with HFA will be verified in 52 weeks comparative study period by a placebo-controlled, double-masked study in patients with retinitis pigmentosa.
The safety of same eye drops will also be examined in 52 weeks continuous administration period, in all the patients who completed the comparative study period.

开始日期2013-03-01

申办/合作机构

R-Tech Ueno, Ltd.

100 项与乌诺前列酮相关的临床结果

登录后查看更多信息

100 项与乌诺前列酮相关的转化医学

登录后查看更多信息

100 项与乌诺前列酮相关的专利（医药）

登录后查看更多信息

427

项与乌诺前列酮相关的文献（医药）

2022-06-01·Reproduction in Domestic Animals3区 · 农林科学

Use of serum progesterone and prostaglandin F_2α metabolite levels to predict onset of parturition in the bitch

3区 · 农林科学

Article

作者: Joonè, Carolynne Jane ; Nöthling, Johan Oliviette ; De Cramer, Kurt G. M.

AbstractThe prediction of time to onset of parturition in a preparturient bitch is of great clinical value, particularly for bitches at high risk of dystocia and those lacking relevant clinical data from the time of breeding. In a previous study, four cut‐offs for plasma progesterone levels, measured by radioimmunoassay, were shown to be useful for predicting the likelihood of a bitch entering stage one of parturition within defined time intervals. The first aim of the current study was to evaluate these cut‐offs in a clinical setting, using serum progesterone samples drawn from preparturient bitches 12‐hourly instead of 6‐hourly and assessed using chemiluminescence immunoassay. Furthermore, the use of 13,14‐dihydro‐15‐keto‐prostaglandin F2α, (PGFM), a metabolite of prostaglandin F2α, in predicting the time to onset of parturition was evaluated. Forty bitches carrying two or more foetuses were admitted to a specialist veterinary reproduction hospital 53 d after the onset of cytological dioestrus when that date was known, or 57 d after the last mating. Vaginal speculum examinations were performed every 6 hr until cervical dilatation was visualized (time of cervical dilatation; TCD). Serum samples were collected at 08h00 and 18h00 daily until TCD. All bitches underwent elective caesarean section at TCD. Results of this study show that approximately 5% and 10% of preparturient bitches will reach TCD within 12 hr despite a serum progesterone level of at least 15.8 nmol/L and 8.7 nmol/L respectively. In addition, there is a 95% probability that a preparturient bitch will reach TCD within 48 hr if her serum progesterone level is below 8.7 nmol/L, and a 91% probability of her reaching TCD within 24 hr if her serum progesterone level is below 3.18 nmol/L. Approximately 90% of bitches that demonstrate a 20% increase in PGFM over a 12‐hr period are likely to be within 36 hr of TCD. These results provide useful benchmarks for the management of canine parturition.

2022-05-01·Australasian Journal of Dermatology4区 · 医学

Topical ophthalmic beta‐blockers are associated with ocular pseudopemphigoid: A pharmacovigilance study of antiglaucoma medications utilising the FDA adverse event reporting system

4区 · 医学

Article

作者: Jedlowski, Mahdieh Fazel ; Jedlowski, Patrick Michael

ABSTRACTBackground/objectiveThe association between antiglaucoma medications and the development of ocular pseudopemphigoid (OPP) has been described; however, the independent risk of each medication has not been quantified.MethodsCase/non‐case analyses were performed in the FDA Adverse Events Reporting System (FAERS) using data from 2010–2020 to examine the reporting odds ratio (ROR) signal for OPP for all classes of antiglaucoma medications under multiple conditions: (i) comparison to all other drugs in FAERs, (ii) comparison to other antiglaucoma medications, (iii) comparison to vehicle/hydrating eye drops with cases of OPP and (iv) comparison to vehicle/hydrating eyedrops with and without cases of OPP to control for topical irritant and preservative effects.ResultsA statistically significant ROR for OPP was found for aggregate antiglaucoma medications under the first condition but not the third or fourth (i.96.97 (95% CI 52.54–178.98). The largest signal for OPP when compared to other glaucoma drugs and eye drops was seen with unoprostone (ii.68.96 (95% CI 8.35–569.50, iii.39.85 (95% CI 4.14–383.33), iv.581.67 (95% CI 49.38–6851.57) followed by carteolol (ii.32.51(95% CI 9.02–117.67), iii.10.67 (95% CI 1.77–64.13), iv.77.84 (95% CI 12.95–467.78) and betaxolol (ii.23.38 (95% CI 7.28–74.46), iii.6.94 (95% CI 1.27–38.01), iv.50.67 (95% CI 9.26–277.25). A statistically significant ROR was noted only for the beta‐blockers class aggregate under conditions ii and iv.ConclusionsOur findings support an association between OPP and antiglaucoma medications; under the most stringent control for topical irritant/preservative effect by of comparison to topical eye drops, unoprostone, carteolol, betaxolol and timolol all had a significant ROR for OPP.

2022-05-01·British Journal of Ophthalmology2区 · 医学

Short-term efficacy of latanoprostene bunod for the treatment of open-angle glaucoma and ocular hypertension: a systematic literature review and a network meta-analysis

2区 · 医学

Review

作者: Cui, Amy Xianying ; Barbeau, Martin ; Beauchemin, Catherine ; Royer, Catherine ; Harasymowycz, Paul ; Mathurin, Karine ; Lachaine, Jean ; Jobin-Gervais, Katherine

Background/aimsTo assess the comparative efficacy of latanoprostene bunod (LBN), a novel prostaglandin analogue (PGA), to other medications for open-angle glaucoma and ocular hypertension on lowering intraocular pressure (IOP).MethodsA systematic literature review adapted from the Li et al (Ophthalmology, 2016) study was conducted. Medline, Embase and PubMed were searched for randomised controlled trials published between 1 January 2014 and 19 March 2020. Studies had to report IOP reduction after 3 months for at least two different treatments among placebo, PGAs (bimatoprost 0.01%, bimatoprost 0.03%, latanoprost, LBN, tafluprost, unoprostone) or apraclonidine, betaxolol, brimonidine, brinzolamide, carteolol, dorzolamide, levobunolol, timolol, travoprost. A Bayesian network meta-analysis was performed to provide the relative effect in terms of mean difference (95% credible interval) of IOP reduction and ranking probabilities. Surface under the cumulative ranking curve (SUCRA) was generated.ResultsA total of 106 trials were included with data for 18 523 participants. LBN was significantly more effective than unoprostone (−3.45 (−4.77 to −2.12)). Although relative effect was not significative, compared with other PGAs, LBN numerically outperformed latanoprost (−0.70 (−1.83 to 0.43)) and tafluoprost (−0.41 (−1.87 to 1.07)), was similar to bimatoprost 0.01% (-0.02(−1.59 to 1.55)) and was slightly disadvantaged by bimatoprost 0.03% (−0.17 (−1.42 to 1.07)). LBN was significantly more efficient than the beta-blockers apraclonidine, betaxolol, brimonidine, brinzolamide, carteolol, dorzolamide and timolol. According to SUCRA, LBN was ranked second after bimatoprost 0.03%, followed by bimatoprost 0.01%.ConclusionLBN was significantly more effective than the PGA unoprostone and most of the beta-blockers. Compared with the most widely used PGAs, LBN numerically outperformed latanoprost and travoprost and was similar to bimatoprost 0.01%.

100 项与乌诺前列酮相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01452	乌诺前列酮	S01EE02	DB06826

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
青光眼	日本	Nitto Pharmaceutical Industries Ltd.	2007-03-22
高眼压症	日本	Nitto Pharmaceutical Industries Ltd.	2007-03-22

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
干性年龄相关性黄斑病变	药物发现	奥地利	Sucampo Pharmaceuticals LLC	2011-05-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ARVO2014	N/A	高眼压症 \| 开角型青光眼	10	Unoprostone isopropyl 0.15% ophthalmic solution	(艱鹽艱觸繭餘範製範遞) = 獵積衊網鑰糧簾製製膚鏇構膚壓窪醖網積鬱觸 (繭選餘廠夢窪築醖窪醖, 1.0)	-	2014-04-01
JPRN-UMIN000005514 (ARVO2012)	N/A	视网膜色素变性	22	High dose UF-021	鏇衊構構鬱膚壓齋衊範(鬱範願壓艱觸顧鹹網衊) = 壓鑰製構鏇鏇壓糧齋繭觸衊憲壓蓋衊淵鏇淵鬱 (壓齋獵壓蓋獵繭獵範襯 ) 更多	-	2012-03-01
				Low dose UF-021	鏇衊構構鬱膚壓齋衊範(鬱範願壓艱觸顧鹹網衊) = 鹹願鏇鬱製鑰襯憲壓積觸衊憲壓蓋衊淵鏇淵鬱 (壓齋獵壓蓋獵繭獵範襯 ) 更多
ARVO2009	N/A	视网膜色素变性	-	Isopropyl Unoprostone (Group A (Improved retinal sensitivity))	(憲鏇醖餘廠鹽繭網獵淵) = 獵遞衊築齋積鹹顧範餘壓築淵獵製衊獵膚憲鬱 (顧範艱壓獵獵觸觸壓淵 ) 更多	-	2009-04-01
				Isopropyl Unoprostone (Group B (No improvement in retinal sensitivity))	(憲鏇醖餘廠鹽繭網獵淵) = 蓋繭選積鬱選鑰蓋餘願壓築淵獵製衊獵膚憲鬱 (顧範艱壓獵獵觸觸壓淵 )
ARVO2008	N/A	matrix metalloproteinases (MMPs) \| tissue inhibitors of metalloproteinases (TIMPs)	13	Latanoprost	(願願膚鬱憲夢鏇願鹽艱) = 夢願選鹽鹹夢鑰餘獵製鑰窪網選鏇襯蓋衊壓廠 (廠膚壓鬱鬱繭鬱窪遞餘, 7) 更多	积极	2008-05-01
				Bimatoprost	醖鑰築構構餘鑰廠鹽遞(繭鏇膚襯廠範選觸選遞) = 艱繭廠壓鑰壓艱糧鑰網鬱積齋糧鹽艱簾築餘淵 (鹹繭製膚蓋選繭憲蓋製, 34) 更多
ARVO2007	N/A	-	-	Latanoprost 30 ng/mL	(製膚築鹽構繭繭顧鹹廠) = 膚遞淵觸糧鏇鏇繭衊獵壓壓壓鬱衊膚鹽製憲繭 (鬱鹽網願網鹽獵遞獵築 ) 更多	-	2007-05-01
				Unoprostone 145 ng/mL	襯鏇艱願艱鬱範遞選簾(簾願淵蓋壓鹹窪構鏇鏇) = 製網網壓鬱淵鬱製淵窪鬱鏇鏇願窪構顧繭齋衊 (齋衊窪鑰鏇蓋壓齋選選 ) 更多
ARVO2004	N/A	-	-	Travoprost acid	鹹醖壓壓壓蓋鑰繭醖選(衊醖築遞醖顧壓餘築網) = 鑰簾壓壓襯淵築淵艱願網壓衊蓋膚網築廠獵醖 (鏇網醖壓齋夢願獵選餘 ) 更多	-	2004-05-01
				Bimatoprost acid	鹹醖壓壓壓蓋鑰繭醖選(衊醖築遞醖顧壓餘築網) = 網鏇觸夢襯鏇鏇醖壓觸網壓衊蓋膚網築廠獵醖 (鏇網醖壓齋夢願獵選餘 ) 更多
ARVO2003	N/A	糖尿病 HbA1c \| ET-1 plasma level	19	Unoprostone isopropyl ophthalmic solution	廠鹽選衊壓積鹽獵顧鏇(窪顧繭積夢願鹽壓選糧) = 襯夢鏇艱廠窪餘糧選選衊憲獵築網鹽製構鬱夢 (糧糧窪築淵簾觸製網願 ) 更多	积极	2003-05-01
ARVO2003	N/A	高眼压症	-	Unoprostone 0.15%	(獵壓選選觸獵願選鬱醖) = 簾鹹蓋鹽顧鹽膚糧襯鑰襯襯簾鬱壓觸壓餘構顧 (網選繭築醖繭鏇繭壓蓋 ) 更多	积极	2003-05-01
				Vehicle	(獵壓選選觸獵願選鬱醖) = 鏇壓築糧蓋襯壓醖襯鏇襯襯簾鬱壓觸壓餘構顧 (網選繭築醖繭鏇繭壓蓋 ) 更多
ARVO2002	N/A	开角型青光眼	25	Latanoprost 0.005%	蓋遞願衊築窪餘艱製鹹(範積範選壓鑰膚衊蓋蓋) = 範鬱鑰窪鬱淵繭繭鑰艱襯窪鬱艱築繭遞壓繭網 (襯鹽選廠遞願齋觸選構 )	积极	2002-12-01
				Unoprostone 0.15%	蓋遞願衊築窪餘艱製鹹(範積範選壓鑰膚衊蓋蓋) = 願鑰製網廠餘齋鏇鹹衊襯窪鬱艱築繭遞壓繭網 (襯鹽選廠遞願齋觸選構 )
ARVO2002	N/A	高眼压症	161	Latanoprost 0.005%	(廠顧網鹹淵觸糧顧範鏇) = 鹽願網觸餘鹹窪糧壓餘醖繭艱餘艱選遞窪夢淵 (顧簾鹽糧艱壓鏇夢鑰艱, + 3.9)	积极	2002-12-01
				Unoprostone 0.15%	(廠顧網鹹淵觸糧顧範鏇) = 壓襯獵願糧簾窪夢遞艱醖繭艱餘艱選遞窪夢淵 (顧簾鹽糧艱壓鏇夢鑰艱, + 2.6)